Business
Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII(TM) - a Novel Topical Antipsoriatic Prescription Drug
Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Exp...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII™ - a Novel Topical Antipsoriatic Prescription Drug\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnvat{\nVERTICAL-ALIGN: TOP\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n LAVAL, QC, Nov. 10, 2020\n \n \n \n \n \n DUOBRII is a topical antipsoriatic medication introduced in\n \n Canada\n \n \n 1\n \n \n \n Positive CADTH recommendation moves DUOBRII closer to federal, provincial and territorial drug plan reimbursement\n \n \n DUOBRII provides the combined action of two compounds, halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug\n \n 1\n \n \n \n Formulated with PRISMATREX™, a proprietary technology, DUOBRII lotion improves the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis\n \n 1\n \n \n \n DUOBRII is manufactured for distribution throughout\n \n Canada\n \n and\n \n the United States\n \n at the Company's\n \n Quebec\n \n manufacturing facility in\n \n Laval\n \n \n \n \n \n LAVAL, QC\n \n ,\n \n Nov. 10, 2020\n \n /CNW Telbec/ - Bausch Health,\n \n Canada\n \n , part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), (\"Bausch Health\" or the \"Company\") today announced that the CADTH Canadian Drug Expert Committee (CDEC) issued a positive recommendation for DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), a combination product composed of a co...